Purchase this article with an account.
Efi Karakosta, Athanasios Vachtsevanos, Melantho Choulidou, Antonia-Ioanna Vasilopoulou, Lazaros Kazantzidis, Dimitrios Tsakpinis, Alexandros Polychronakos; Assesment of patients treated with ranibizumab for retinal vein occlusion (RVO). Invest. Ophthalmol. Vis. Sci. 2014;55(13):3914.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the safety and efficacy of intraocular ranibizumab injections in patients with macular edema after ischemic and non-ischemic retinal vein occlusion (RVO).
We included 30 patients with macular edema, 10 patients after central RVO and 20 patients after branch RVO treated with ranibizumab. Early Treatment Diabetic Retinopathy Study best corrected visual acuity, central retinal thicknes (CRT), fundus photographs, and fluorescein angiograms (FFA) were evaluated, and the incidence and severity of adverse events were documented.
Patients with BRVO had improvement of BCVA while CRVO patients had improvement according the first assessment of BCVA. Patients with ischemic CRVO with extensive areas of retinal non-perfusion capillary greater than 10 disc areas was associated with an increased risk of neovascularization thus a poorer prognosis on the outcome of the treatment.
Intraocular injections of ranibizumab were well tolerated and associated with reduction in macular edema and improvement in visual acuity. Ranibizumab provides an effective and safe treatment for macular edema after RVO.
This PDF is available to Subscribers Only